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The steady and dramatic increase in the incidence of Alzheimer’s disease (AD) and the lack of effective treatments have stimulated
the search for strategies to prevent or delay its onset and/or progression. Since the diagnosis of dementia requires a number of
established features that are present when the disease is fully developed, but not always in the early stages, the need for a biological
marker has proven to be urgent, in terms of both diagnosis and monitoring of AD. AD has been shown to affect peripheral
blood mononuclear cells (PBMCs) that are a critical component of the immune system which provide defence against infection.
Although studies are continuously supplying additional data that emphasize the central role of inflammation in AD, PBMCs have
not been sufficiently investigated in this context. Delineating biochemical alterations in AD blood constituents may prove valuable
in identifying accessible footprints that reflect degenerative processes within the Central Nervous System (CNS). In this review, we
address the role of biomarkers in ADwith a focus on the notion that PBMCsmay serve as a peripheral laboratory to findmolecular
signatures that could aid in differential diagnosis with other forms of dementia and in monitoring of disease progression.
1. Introduction
The prevalence of dementia has increased globally, most
noticeably in the ageing populations of the developed world.
Alzheimer’s disease (AD) is the most common type of
dementia (60% of cases). Individuals affected by AD are
5.4 million in the United States and more than 33.9 million
worldwide [1].Moreover, AD prevalence is estimated to triple
over the next 40 years and this will place a heavy burden on
society and its health-care systems in terms of both economic
costs and human impacts. The steady and dramatic increase
in the incidence of AD and the lack of effective treatments
have stimulated the search for strategies to prevent or delay
its onset and/or progression.
There is general agreement that the epidemiological
impact of dementia can be reduced by detecting and treating
classical vascular risk factors since different studies provide
evidence in favour of a coexistence of vascular and degener-
ative components in its pathogenesis [2].
In western countries vascular dementia (VD) is the
second most common cause of dementia after AD among
the elderly. A meta-analysis of the European studies on the
incidence of dementia showed that VD constitutes 17.6%
of all dementias [3]. In Europe and North America, AD is
more common than VD in a 2 : 1 ratio; in contrast, in Japan
and China VD accounts for almost 50% of all dementias.
Also, the possibility of concomitant AD often confounds the
relationship between cerebrovascular disease and VD.
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AD is characterized by neurofibrillary tangles (NFT) and
extracellular amyloid deposits. The former are composed of
intraneuronal aggregates of hyperphosphorylated tau pro-
teins and the latter are made of amyloid-beta (A𝛽) peptides
stemming from the sequential cleavage of a transmembrane
precursor named amyloid precursor protein (APP).
Vascular pathology, namely arteriosclerosis, endothelial
proliferation, and neovascularization, have been often found
to be associated with NTF and amyloid plaques [4].
A number of autopsy studies have confirmed that among
cases of dementia, AD-related pathology was associated with
vascular lesions in nearly one-third of cases [5]. In addition,
many epidemiological reports have demonstrated that the
presence of vascular factors increases the risk of developing
AD.
However, it is still a matter of controversy whether neu-
rodegenerative AD-like disease and cerebrovascular lesions
are coexisting but unrelated pathologies or whether they rep-
resent different results of synergistic pathogenicmechanisms.
It is hypothesized that an alteration of the neurovascular
unit, which is the functional unit encompassing vascular cells,
astrocytes, and perivascular neurons, is an early event in the
pathogenesis of AD [6]. Dysfunction of the neurovascular
unit results in impaired blood brain barrier (BBB) functions,
dysregulation of cerebral blood flow, and impairment of A𝛽
clearance leading to an increase of oligomers and soluble
A𝛽 forms [7]. Vascular oxidative stress and inflammation
underlie many of these deleterious effects and are potential
therapeutic targets even if, at present, there is no cure for AD
and only a few medications aimed at slowing down memory
deficits and clinical symptoms are available, with limited
benefits.
Consequently, there is a pressing need for the identifica-
tion of biomarkers that will aid in the differential diagnosis
between AD and other forms of dementia and that will allow
the detection of AD at early stages. Within the scenario of
dementia, biomarker research may thus play an important
role in paving theway towards novel diagnostic or therapeutic
strategies.
2. Biomarkers
A biomarker is a characteristic that can be objectively
measured and evaluated as an indicator of normal bio-
logical processes, pathogenic processes, or pharmacological
responses to a therapeutic intervention [8, 9]. Many tests
commonly used in clinical practice are biomarkers; biochem-
ical tests provide soluble biomarkers, whereas physiological
assessment and imaging measures provide anatomical and
functional biomarkers. The majority have been identified on
the basis of biological insight or underlying physiology. With
increasing knowledge and practical experience,many of these
tests have evolved into measurable end points in clinical
research, applied as indicators of change, be it for the better
or for the worse [10].
Biomarkers have also gained an important role in the field
of clinical management and have established a close link with
bedside medicine, by providing metrics of quality in medical
care alongside meaningful costing. With effective translation
into many clinical guidelines, biomarkers can facilitate the
delivery of evidence-based medical care [11].
The evaluation of biomarkersmay aid in the identification
of diseases and may also allow correlations to be made with
the progression or the susceptibility to a disease or a given
treatment.
Yet, single biomarkers are unlikely to capture the complex
process of human pathophysiology. Thus research may need
to be geared towards sets of biomarkers, reflecting different,
but intercalated, processes, which may enable a better assess-
ment of disease states.
Biomarkers can be measured, for instance, in saliva,
sweat, breath, blood/serum, urine, and cerebrospinal fluid
(CSF). The fact that the collection of these biological fluids
is significantly less invasive than biopsies is an important
practical issue when studying neurodegenerative disorders
like AD [12].
It has been reported that the sensitivity (definitely pos-
itive/(definitely positive + false negative)) of an “ideal”
biomarker to detect AD should be at least 85%. Similarly,
the specificity (definitely negative/(definitely negative + false
positive)) in differentiating AD patients from controls and
from patients with other forms of dementia should be at least
75% [10].
2.1. Biomarkers and Alzheimer. Despite the enormous
advances in modern medicine, the diagnosis of AD remains
largely clinical, based on patient history/examination,
neuropsychological testing, and imaging techniques.
Unfortunately the clinical diagnosis of AD suffers from
limitations in that it only allows us to speak of probable or
possible AD [13] with a 93% sensitivity and a 55% specificity.
Furthermore, the diagnosis becomes far more difficult in the
case of early or unusual presentations of the disease.
With the expansion of current knowledge on AD and
the increasing availability of technical tools, there is an
emerging need for the development of accurate biochemical
and imaging tests that support the diagnosis [14, 15]. In
this context the diagnostic criteria for AD proposed in 2007
[14] highlight the usefulness of genetic studies since they
would enable a definite diagnosis to be made based on
the demonstration of mutations in any of the three genes
responsible for autosomal dominant disease: the gene forAPP
on chromosome 21, for presenilin 1 (on chromosome 14), and
for presenilin 2 (on chromosome 1).
As to the more prevalent sporadic cases of AD, the need
for a biological marker has proven to be urgent, for both the
diagnosis and monitoring of the disease [16, 17].
Indeed, an ideal biomarker for AD would assist in the
identification of preclinical disease, early disease diagnosis,
staging of disease progression, and response to treatment
[18]. Early diagnosis and identification of preclinical AD are
particularly important issues considering the development of
underlying neuropathology in those yet to display clinical
symptoms. In particular, Mild Cognitive Impairment (MCI)
is a well-described prodromal state of cognitive decline
preceding dementia, with an accelerated conversion to AD
estimated at 10–12% per year [19].
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Over the past decade, biomarker discovery has become a
rapidly advancing area of AD research.
With the development of structural, functional, and
molecular techniques, neuroimaging is increasingly being
employed as a diagnostic and prognostic tool in AD. Quan-
titative magnetic resonance imaging (MRI) is used to assess
neurodegenerative changes in AD, which include reduc-
ing whole brain volume and cortical thickness associated
with ventricular enlargement [20]. Early degeneration is
also apparent in the hippocampus, entorhinal cortex, and
medial temporal lobe of AD patients relative to controls [21].
In fact, MRI-determined hippocampal atrophy is currently
the most established structural biomarker for AD and has
been shown to predict the conversion from MCI to AD
in about 80% of cases [22]. Additional neuroimaging tech-
niques include functional MRI (fMRI), positron emission
tomography (PET), and single-photon emission computed
tomography (SPECT) which reveal abnormalities in brain
synaptic activity, metabolism, and perfusion, respectively.
Recent advances include the development of a number of
amyloid-binding compounds, the most extensively studied
being 11C-PIB (Pittsburgh Compound B, PIB). Several PET
studies have detected an increased uptake of PIB in AD
patients, which was found to correlate with the extent of
cerebral atrophy and memory impairment [23]. Notably,
longitudinal studies suggest that PIB imaging is able to
predict the progression from normal cognition and MCI to
symptomatic AD [24].
In view of the close relationship of the CSF with the
brain and spinal cord, it is believed that the composition
of this fluid may reflect biochemical changes in the CNS
and thus provide information on the pathological changes
occurring in neurodegenerative disorders [18].Multiple stud-
ies have examined CSF for potential AD biomarkers. It is
generally recognized that AD subjects compared to age-
matched controls exhibit decreased CSF levels of soluble
A𝛽42 and increased CSF levels of total tau and phosphotau
[25]. Importantly, diagnostic accuracy is improved by using
the tau/A𝛽42 ratio instead of either single biomarker, and this
is reflected in an increase in sensitivity and specificity to 86%
and 97%, respectively [26]. Moreover, this combination also
appears to predict the subsequent development of AD in both
cognitively normal and MCI patients [27, 28]. These findings
have thus established CSF A𝛽42 and tau as the most sensitive
and specific diagnostic and predictive biomarkers for AD.
It should however be remarked that although neuroimag-
ing and CSF biomarkers seem to be the most promising,
they also carry some limitations.They are generally expensive
to perform routinely and lumbar puncture is invasive and
often unpleasant. Moreover a large variability exists in the
literature as to CSF biomarker diagnostic accuracies and cut-
offs, hampering or delaying their everyday application in the
clinical setting [29, 30] and their potential use as indicators of
prodromal AD.
Also, it is worth noting that the process of biomarker
discovery involvesmany critical steps including study design,
sample preparation, protein and peptide separation and iden-
tification, and bioinformatics and data integration issues that
must be carefully controlled before achieving independent
confirmation and validation.
Lastly, patient age is an important confounding factor
in these biomarker studies and could explain some of the
variability in published diagnostic accuracies and cut-offs
[30]. Indeed a consistent number of subjects affected by Lewy
Body Dementia (LBD), Frontotemporal Lobar Degeneration
(FTLD), VD, and Corticobasal Degeneration (CBD) display
an AD-like CSF biomarker profile [31].
3. Inflammation and Alzheimer
In the human brain several cell types are responsible for
initiating and amplifying a specific inflammatory response.
In AD signs of an inflammatory activation of microglia
and astroglia are present both inside and outside amyloid
deposits. Cell cultures and animal models suggest an interac-
tive relationship between inflammatory response activation,
reduced neuronal functioning, and amyloid deposition. Fur-
thermore cells associated with extracellular plaques within
AD brains can produce a variety of cytokines, chemokines,
and other related proteins that influence plaque and tangle
formation [32].
There is strong evidence that inflammation exacerbates
neuronal loss [33, 34]. In fact, local inflammatory processes
can exert a direct neurotoxicity, interfere with A𝛽 expression
and metabolism, and maintain a chronic intracerebral acute
phase protein secretion, which in turn favours formation of
A𝛽 oligomers [35].
On the other hand, microglial activation leads to an
increased brain expression of major histocompatibility com-
plex type II and an increased secretion of proinflamma-
tory cytokines and chemokines such as interleukin-1 (IL-1),
interleukin-6 (IL-6), tumour necrosis factor-𝛼 (TNF-𝛼), and
interleukin-8 (IL-8), as well as complement components and
acute phase proteins [36].
A “cytokine cycle” has been proposed where [37] the anti-
inflammatory cytokines (IL-4, IL-10, and IL-13) regulate A𝛽-
inducedmicroglial/macrophage inflammatory responses and
modify the microglial activity surrounding amyloid neuritic
plaques [38]. Such cytokines can inhibit the induction of IL-
1, TNF-𝛼, and MCP-1 in differentiated human monocytes
and, above all, IL-10 causes dose-dependent inhibition of the
IL-6 secretion induced by A𝛽 in these cells and in murine
microglia [37].
Accordingly, several reports make it appears that the risk
of AD is substantially influenced by polymorphisms in the
promoter region and other untranslated regions, of genes
encoding inflammatory mediators. Alleles that favour an
increased or decreased expression of inflammatorymediators
are more frequent in patients with AD than in controls [39].
A𝛽 has also been shown to induce a phagocytic response
in microglia, suggesting a neuroprotective defense mecha-
nism [40]. This is, however, coupled to an increased release
of signalling molecules and reactive oxygen and nitrogen
species, which may further promote neuronal damage [41].
Despite these findings, clinical trials of nonsteroidal anti-
inflammatory drugs (NSAIDs) in AD patients have been
disappointing [42].
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3.1. Peripheral Blood Mononuclear Cells. Nowadays it
remains the need for a reliable, minimally invasive, and
inexpensive biomarker for dementia, leading many to
investigate peripheral blood. Blood collection is simple,
inexpensive, and less invasive than lumbar puncture,
allowing for repeated sampling. Approximately 500mL of
CSF is absorbed into the blood daily [43] and there is also
evidence for blood-brain barrier (BBB) dysfunction in AD
and other neurodegenerative disorders, which may enhance
protein exchange between both fluids [44]. Consequently,
the leakage of CNS metabolites into the peripheral system
may reflect neurodegenerative disease status and could offer
a suitable source of disease biomarkers.
AD also affects PBMCs that are defined as any blood
cell with a round nucleus (i.e., lymphocytes, monocytes, or
macrophages). These blood cells are a critical component of
the immune system which provide defence against infection
and respond to intruders. The lymphocyte population con-
sists of CD4+ andCD8+T cells, B cells and natural killer cells,
CD14+ monocytes, basophils, neutrophils, eosinophils, and
dendritic cells.
Although studies are continuously providing additional
data that emphasize the central role of inflammation in AD,
PBMCs have not been sufficiently investigated in this context.
Indeed, only scant studies have used PBMCs to measure
cytokine release, showing a significantly different production
of these inflammatory components in AD and MCI subjects
compared to controls [39, 45] (Figure 1) as well as a greater IL-
1 and TNF-𝛼 production, associated with an increased risk of
AD, in elderly controls [46].
Delineating biochemical alterations in AD blood con-
stituentsmay enable the identification of accessible footprints
that mirror degenerative processes within the CNS.
Moreover PBMCs could reflect inflammatory
mechanisms in a more specific way compared with the
serum/plasma, and PBMC-associated biomarkers could thus
provide novel insight into the pathogenesis of AD.
In the following paragraphs we discuss the potential of
PBMCs to serve as a peripheral laboratory to find molecular
signatures in AD that could aid both in the differential
diagnosiswith other forms of dementia and in themonitoring
of disease progression.
4. Peptidyl-prolyl cis-/trans-Isomerase
Pin1 in PBMCs
The peptidyl-prolyl cis-/trans-isomerase Pin1 is a cytosolic
protein that isomerizes the peptide bond of a phosphorylated
serine or a phosphorylated threonine followed by a proline
(pSer-/pThr-Pro). Pin1 catalyzes the cis-/trans-isomerization
of its substrates, consequently potentiating the accessibility
of the phosphate residue for further dephosphorylation by
protein phosphatases such as the protein phosphatase PP2A.
Alternatively, the binding of Pin1 to other highly phos-
phorylated substrates can repress their dephosphorylation
by calcineurin. Therefore, through isomerization of pSer-
/pThr-Pro, Pin1 regulates the function or degradation of a
growing number of proteins including transcription factors
and cytoskeletal, mitotic, or proapoptotic proteins [47].
Pin1 consists of 2 functional domains. The binding
domain corresponds to the amino-terminal region consisting
of a group IV WW domain (Trp-Trp domain) that specifi-
cally binds to pSer-/pThr-Pro motifs. The carboxyl-terminal
region is the catalytic domain [48]. Pin1 substrate-binding
and isomerase activity are regulated by phosphorylation.
Indeed, 3 phosphorylation sites of Pin1 have been character-
ized. In particular, serine 16 is located in the WW domain
and is phosphorylated by protein kinase A. Phosphorylation
of Pin1 at serine 16 represses substrate recognition [49].
Pin1 has several additional putative phosphorylation sites
(e.g., human Pin1 has 29 residues of serine or threonine and
3 tyrosines).
Phosphorylation of proteins is a key signalling mecha-
nism in diverse of physiological and pathological processes.
Pin1-catalysed conformational changes can have profound
effects on phosphorylation signalling by regulating a spec-
trum of target activities. Interestingly, Pin1 deregulation
is implicated in a number of conditions, notably ageing
and age-related diseases, including cancer and AD. Pin1 is
overexpressed in most human cancers; it activates numerous
oncogenes or growth enhancers and also inactivates a large
number of tumour suppressors or growth inhibitors. By
contrast, ablation of Pin1 prevents cancer but eventually leads
to premature ageing and neurodegeneration. Recent studies
have demonstrated the reemergence within the brain of cell
cycle proteins as patients progress from MCI into AD. Pin1
plays an important role in regulating the activity of key
proteins, such as CDK5, GSK3-𝛽, and PP2A, that are involved
not only in the cell cycle but also in the phosphorylation state
of Tau [50].
Indeed, Pin1 facilitates tau dephosphorylation [51] and
regulates APPmetabolism, thus providing additional support
to the hypothesis that it has a neuroprotective function
against AD [52–56].
It has been reported that Pin1 activity is repressed by
oxidation in AD [52–58] and that Pin1 is localized to granular
vesicles in AD and FTD but not to tau aggregates [55, 59–63].
It should be remarked that the expression and activity of
Pin1 are tightly regulated at a transcriptional level and that
a Pin1 gene polymorphism (−842G/C) has been found to be
associated with reduced levels of Pin1 in blood cells and with
an increased risk for AD in an Italian cohort [64].
Interestingly, a depletion of the soluble form of Pin1 has
been described in neurons from AD subjects [57, 65] and
differences in Pin 1 molecular and biochemical parameters
have been reported in PBMCs from late-onset AD (LOAD)
compared with control subjects [66].
In particular, in PBMCs from LOAD we observed a
significant increase in Pin1 gene expression together with a
significant decrease in gene promoter methylation [66].
This latter finding holds particular relevance, since so
far little is known about epigenetic patterns in AD. More-
over, epigenetic mechanisms have already been proposed as
markers of AD in PBMC-derived DNA [67] and it has been
claimed that DNA methylation in peripheral cells could be
taken as a model of epigenetic gene regulation in the brain
[68].
BioMed Research International 5
10
9
8
7
6
5
4
3
2
1
0
M
ito
ge
n-
sti
m
ul
at
ed
 cy
to
ki
ne
 p
ro
du
ct
io
n 
(p
g/
m
L)
IL-6
(a)
IL-10
70
60
50
40
30
20
10
0
M
ito
ge
n-
sti
m
ul
at
ed
 cy
to
ki
ne
 p
ro
du
ct
io
n 
(p
g/
m
L)
(b)
IL-6
3
2.5
2
1.5
1
0.5
0
AD
CT
𝛽
-a
m
yl
oi
d-
sti
m
ul
at
ed
 cy
to
ki
ne
 p
ro
du
ct
io
n 
(p
g/
m
L)
(c)
100
80
60
40
20
0
P = 0.023
IL-10
AD
CT
𝛽
-a
m
yl
oi
d-
sti
m
ul
at
ed
 cy
to
ki
ne
 p
ro
du
ct
io
n 
(p
g/
m
L)
(d)
Figure 1: PBMCs of AD patients and age- and sex-matched controls (CT) were stimulated with a mitogen (LPS) and with a pool of three A𝛽
peptides (A𝛽 fragment 25–35; A𝛽 fragment 1–40; A𝛽 fragment 1–16). The production of IL-10 and IL-6 was measured by means of ELISA.
There were no differences in mitogen-stimulated IL-6 and IL-10 production in AD and controls. In contrast, when A𝛽-stimulated production
of IL-6 and IL-10 was analysed, a marginally increased IL-6 production and a significantly decreased IL-10 generation were observed in AD
patients compared to controls, suggesting an antigen-specific impairment in the production of these cytokines.
We have also shown that in LOAD subjects Ser16
phosphorylation levels of Pin1 were lower than in controls
(Figure 2).
Phosphorylation of Pin1 must therefore be a key factor in
regulating its localization, function, and metabolism and tau
seems to be involved in controlling the balance between the
phosphorylation/dephosphorylation of Pin1 in brain cellular
lysate [69].
Moreover, Wang et al. [70] suggested that reduced Pin1
activity in the frontal cortex of patients withMCI contributes
to the initial accumulation of hyperphosphorylated tau and is
then followed, in a more advanced stage of the disease, by a
compensatory upregulation of the Pin1 gene that counteracts
A𝛽 plaque formation.
In particular, with regard to our finding of lower Ser16
phosphorylation levels of Pin1 in LOAD subjects relative to
controls, different interpretations can be put forward: the
presence in LOAD patients of rare gene variants of Pin1 that
could influence its phosphorylation state [71] and the effects
on Pin1 of a higher blood concentration of A𝛽42 [72]. In
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Figure 2: Scatter dot plots showing the distributions of molecular and biochemical parameters of PBMCs from controls (CT) and LOAD:
activity (a), Ser16 phosphorylation (b), methylation (c), and gene expression (d). The lines across the boxes indicate median values.
keeping with the latter hypothesis, in rat hippocampal cells,
treatment with A𝛽42 oligomers has been shown to promote
a transient Pin1 dephosphorylation on Ser16 associated with
a decrease in phosphorylated TauThr231 [73]. Whatever the
specific explanation is, the modifications of Pin1 observed
in LOAD subjects make it reasonable to suppose that Pin1
is involved in AD [74] and that epigenetic mechanisms
(i.e., Pin1 promoter methylation) play a role in the disease.
Therefore, alterations in easily accessible peripheral cells may
prove to be valuable biomarkers in the diagnosis and follow-
up of AD and, potentially, also of some tauopathies.
5. Epigenetics
Literally meaning “above the genome” the epigenome com-
prises the heritable changes in gene expression that occur in
the absence of changes to theDNA sequence itself. Epigenetic
mechanisms include chromatin folding and attachment to
the nuclear matrix, packaging of DNA around nucleosomes,
covalentmodifications of histone tails, andDNAmethylation
in the whole genome and/or in specific gene promoters [75].
DNAmethylation, in particular, consists of the transfer of
a methyl group to position 5 of the cytosine pyrimidine ring
of a cytosine guanine dinucleotide (CpG), which ultimately
blocks the binding of transcription factors causing chromatin
compaction and gene silencing [76].
The influence of regulatory small RNAs and microRNAs
on gene transcription is also increasingly recognized as a key
mechanism of epigenetic gene regulation [77].
Indeed, microRNAs (miRNAs), small regulatory RNAs
in cells, probably constitute one of the most investigated
extracellular RNAs in body fluidsand the levels of certain
miRNAs in the circulation correlate well with different patho-
logical conditions (i.e., miR-499 and miR-1 are associated
with cardiovascular conditions) [78–81].
Epigenetic mechanisms are important in cell growth and
differentiation [82]. Epigenetic change can be stochastic [83]
or internally orchestrated as part of ageing [84]. Longitudi-
nal changes in global and gene-specific DNA methylation
clusters within families suggest there is a genetic control to
methylation status [85].
Epigenetics is destined to change across the lifespan.
In fact a loss of global DNA methylation and promoter
BioMed Research International 7
hypermethylation of several specific genes occurs during
ageing.
In particular ageing-associated DNA hypermethylation
occurs predominantly in genes involved in the development
of anatomical structures, organs, andmulticellular organisms
and in the regulation of transcription.
This phenomenon may be considered a new aspect of the
age remodeling process, a continuous adaptation of the body
to the deteriorative changes occurring over time. However, it
is not clear how relevant these epigenetic changes are in the
context of functional changes in gene expression [86].
Inappropriate epigenetic changes are associated with
many diseases including cancer [87], Rett syndrome [88],
Beckwith-Wiedemann syndrome [89], and other imprinting
disorders.
Environmental signals can trigger epigenetic responses
and may be an important mechanism by which environmen-
tal exposures are associated with disease [90]. Furthermore,
epigenetic mechanisms may play an important role in the
developmental origins of adult health and disease by pro-
viding a mechanism underlying the latent effects of adverse
fetal, infant, and childhood environments on late-life chronic
disease [91–93].
5.1. Epigenetic Epidemiology and Alzheimer’s Disease. Epi-
genetic epidemiology is the study of the effects of heri-
table epigenetic changes on the occurrence and distribu-
tion of diseases in populations [94]. This research includes
both transgenerational and intraindividual cellular epigenetic
inheritance systems. Epigenetic changes are associated not
only with ageing [95, 96], but also with psychiatric outcomes
[97, 98] and neurodegeneration [99].
Evidence for the role of epigenetics in AD pathogenesis
can be found in human studies of various tissues, in animal
models, and in cell cultures [100–102]. Global changes asso-
ciated with AD have been observed in DNA methylation,
miRNAs, and histone modifications.
Discordant data have been reported on specific epigenetic
modifications of tau- and amyloid-processing genes. On the
one hand an altered regulation was reported across multiple
brain regions [103–105], and on the other hand no differences
were seen in DNA methylation in regions associated with
MAPT, PSEN1, and APP [103].
Human postmortem case-control studies have demon-
strated global hypomethylation in the entorhinal cortex of
AD subjects [106] and in the temporal neocortex of an AD
monozygotic twin relative to the cognitively normal twin
[107].
An AD case-control study in the postmortem human
parietal lobe cortex has revealed a differential regulation
of several miRNAs, including miR-204, miR-211, and miR-
44691 [108].
Age-matched AD cases have been found to exhibit an
increased neuronal global phosphorylation of histone 3
relative to controls, as determined by immunolabeling in
the hippocampus, and such histone modification suggests
mitotic activation [109].
In experiments where neuroblastoma cells were cultured
under low folate and vitamin B12 conditions, PSEN1 and
BACE1 were hypomethylated, mRNA expression of BACE1
and PSEN1was significantly induced, andA𝛽 productionwas
increased [110].
An additional study using human neuroblastoma cells
and male rat brain tissue reports that APP mRNA expression
is repressed by thyroid hormone (T3) sensitive histone
modifications [111].
5.2. Epigenetics in PBMCs. The study of gene regulation in
blood cells from living patients offers the possibility to go
through the whole history of the disorder (including the
response to pharmacological, metabolic, and environmental
events) in a more comprehensive perspective, compared to
postmortem studies which allow only pinpoint assessment.
It is important to note that PBMCs may also be a useful
model of epigenetic gene regulation in the brain [68]. In fact,
it has been shown that PBMCs sharemuch of the nonsynaptic
biochemical environment of neurons and contain the full
complement of epigenetic enzymes found in most tissues,
including neurons and peripheral nucleated cells [112, 113].
For instance, our group has investigated the role of DNA
methylation in the PBMCS from LOAD subjects compared
to controls and has demonstrated an altered Pin1 gene
expression and promoter methylation [66], as detailed above,
along with changes in fatty acid amide hydrolase (FAAH) and
5-lipoxygenases (5-LOX) genes (Faah EC 3.5.1.99 and Alox5
EC 1.13.11.34), proteins, and activity [114].
Also, by comparing DNAmethylation of Faah and Alox5
promoters we found a direct correlation between these two
genes [114, 115].
It has been shown that oxygenation of the FAAH sub-
strates by lipoxygenase activity modulates recognition of
these molecules by their protein targets [116], with potential
implications for their biological activity [117].
These results might suggest that a parallel increase of
FAAH and 5-LOX expression in AD patients could evoke a
sustained inflammatory condition, thus reinforcing neurode-
generation [114, 115].
This finding in peripheral cells is in agreement with
previous results in postmortemADbrains [118], where FAAH
protein upregulation within plaques was suggested to lead
to an increase in metabolites from endocannabinoid anan-
damide (AEA) degradation (such as arachidonic acid). Such
metabolites could contribute to the inflammatory process
occurring in AD.
Recently, there has been considerable interest in exploring
the therapeutic potential of anti-inflammatory agents to
prevent, treat, or slow down the progression of AD [119].
However, nonsteroidal anti-inflammatory drugs were found
to be ineffective in AD patients with mild to moderate
cognitive impairment [120], emphasizing the importance
of an early diagnosis and therapy. Furthermore, pharma-
cological interventions based on chronic treatment with
COX inhibitors, or treatment with anticytokine therapies, are
not ideal for a long-term use, due to their gastrointestinal
(COX1-selective inhibitors), cardiovascular (COX2-selective
inhibitors), and immunosuppressive (anticytokine therapies)
side effects [121].
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Taken together, these lines of research converge towards
the notion that novel anti-inflammatory targets may provide
a safer strategy for the prevention and the treatment of AD.
In such scenario PBMCs stand out as potential peripheral
markers of disease within the CNS.
6. Adenosine A
2A Receptors in PBMCs
Nutritional alterations have been linked to the epigenetic
modulation of someAD-related genes and seem to play a role
inADpathology.There is also evidence in favour of the epige-
netic modulation of genes involved in the pathways activated
by some dietary factors, both in ageing and disease, further
supporting the involvement of epigeneticmechanisms in AD.
A number of dietary elements have been reported to be either
risk or protective factors for the development of AD. These
include fat, fatty acids, antioxidants, fish, vitamins, alcohol,
and, more recently, caffeine [122].
The neuroprotective effect of caffeine consumption on
AD pathology is currently emerging from both basic and
epidemiological studies [123]. In vitro and animal studies
have provided convincing data on caffeine’s neuroprotective
effects against and in the presence of ADpathology [124–126].
Human studies have begun to demonstrate the presence of
a similar neuroprotective role in the ageing and demented
population.
However, due to the conflicting results from some lon-
gitudinal studies, there is no consensus about the role of
caffeine in the onset of AD [124–128].
Caffeine is one of the most consumed psychoactive drugs
and acts mostly by blocking adenosine receptors [129]. The
purine ribonucleoside adenosine (Ado) is a naturally occur-
ring metabolite that is ubiquitously distributed throughout
the body as ametabolic intermediary. Intra- and extracellular
Ado levels rise in response to physiological stimuli and with
metabolic/energetic perturbations, inflammatory challenges,
and tissue injury [130, 131].
The physiological responses to Ado take place as a result
of the binding and activation of different transmembrane
receptors: the high-affinity A
1
and A
2A (A2A) receptors, the
low-affinity A
2B receptor, or the low-abundance A3 receptor
[132].
These receptors are G-protein coupled receptors that
regulate, in opposite directions, the secondmessenger cAMP;
while A
1
is inhibitory Gi-coupled, A
2A is excitatory Gs-
coupled, thereby decreasing and increasing cAMP levels,
respectively [133].The activation of these receptors is also able
tomodulate Ca2+ channels and the phospholipase C pathway.
Through these actions and by modulating both the release
and the uptake of different neurotransmitters, the balance
between the activation of adenosine A
1
and A
2A receptors
allows the fine tuning of synaptic transmission and plasticity
in the hippocampus [134].
In particular A
2A is present in a wide variety of tissues,
including the nervous system and the peripheral immune
system, where they display different levels of expression:
significant levels in neurons and peripheral cells (lympho-
cytes and neutrophils) and lower levels in glial cells [132].
The different levels of expression of A
2A in different tissues
are consistent with the sophisticated, multifaceted neuro-
chemical, and molecular effects of the Ado system. On the
basis of in vitro [135, 136] and in vivo [137] studies, it has
become clear that A
2A, through complex mechanisms which
are still poorly understood [138–141], plays a critical role
in the modulation of inflammatory reactions, influencing
functional outcome in a broad spectrum of pathologies
including neurodegeneration [142, 143].
Moreover it has been demonstrated that A
2A is able to
prevent A𝛽-induced synaptotoxicity in animal models and
cell cultures [144] and it has been shown to control NMDA
currents and glutamate outflow in the hippocampus [145,
146].
Contrasting data have been reported so far on the
beneficial/detrimental effects of A
2A on brain cells [147]. The
blockade of A
2A alleviates the long-term burden of brain
disorders such as ischaemia, epilepsy, Parkinson’s disease, or
AD [138, 145, 148, 149]. On the other hand, agonists of A
2A can
protect the CNS against several insults, including ischemia
and excitotoxins [143, 150].
In the periphery A
2A contributes to coronary endothelial
dilatation in mice [151], can inhibit endothelial apoptosis
[152], and preserves vascular reactivity following hemor-
rhagic shock in rats [153].
We recently investigated A
2A gene expression and density
in the PBMCs of patients with amnesticMCI (a-MCI), multi-
ple cognitive domainMCI (mcd-MCI), outright AD,VD, and
controls. We found that A
2A expression is upregulated in the
peripheral cells of a-MCI but not AD subjects, supporting an
involvement of theAdo system in the early stages of AD [154].
We also showed that A
2A expression is lower in the PBMCs of
subjects with VD than AD, highlighting its possible relevance
as a biomarker that may help differentiate two forms of
dementia that are often closely associated (Figure 3).
Indeed, ROC analysis data showed that A
2A possesses a
moderate degree of sensitivity and specificity for identifying
VD patients from a heterogeneous group composed of VD
and AD patients. The lower A
2A expression in VD compared
to AD subjects seems to suggest a differential role of the Ado
system in these dementias [155].
Themethylation of the ADORA2A promoter gene, which
codes for A
2A, may explain its different expression in these
pathological conditions as well as in the ageing process, as
already mentioned [156].
Moreover, A
2A represents themainAdo receptor involved
in inflammation and it is interesting to note that also other
inflammatory biomarkers are differently expressed inVDand
AD subjects, such as alpha1-globulin and alpha2-globulin in
the serum [157] and C3a and C4a in the CSF [158].
On the other hand the decreased A
2A levels in VD could
be a defence mechanism since it has been demonstrated
that pharmacologic inactivation or genetic deletion of A
2AR
reduces neuronal injury after global and focal cerebral
ischemia in many animal models [149, 159, 160]. From our
results it can be concluded that A
2A may play an important
but differential role in both types of dementia: its upregu-
lation in the preclinical stages of AD could counterbalance
the existing inflammatory state and its downregulation in
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Figure 3: (a) Scatter plot of A
2A gene expression in PBMCs from VD, mcd-MCI, controls (CT), AD, and a-MCI subjects (the lines represent
the mean value for each group). ∗𝑃 < 0.001 versus AD; #𝑃 < 0.05 versus a-MCI. (b) Representative picture of the western blot analysis of the
A
2A densities in PBMCs extracts, running in duplicate, from one subject from the VD, CT, AD, and a-MCI groups, respectively.
VD could reflect the effects of A
2A on the brain vasculature
[161]. It can therefore be suggested that A
2A could serve as a
biomarker in the differential diagnosis between VD and AD.
7. Conclusions
Peripheral cells and in particular PBMCs seem to directly
participate to neurodegenerative processes.They play critical
roles in immune response, metabolism, and communication
with other cells as already pointed out many years ago
[162]. Moreover, PBMCs have been shown to share much
of the nonsynaptic biochemical environment of neurons
and contain the full complement of epigenetic enzymes and
machinery, which are found in both neurons and peripheral
nucleated cells, as in most other tissues.
The substantial evidence in favour of the notion that
PBMCs provide a window into the CNS holds particular rel-
evance in neurodegenerative disorders in which, unlike most
other diseases, the affected tissue is not directly accessible
to evaluation. On a final note, it should be mentioned that
the value of biochemical dysfunctions in PBMCs as mirrors
of CNS defects appears to extend well beyond dementia.For
instance, FAAH and other elements of the endocannabinoid
system show alterations in the blood that resemble those
within the CNS in a broad spectrum of clinical conditions
including Parkinson’s and Huntington’s disease, multiple
sclerosis, schizophrenia, minor depression, and headache
[163].
Nowadays we do not know if PBMCs biomarkers are
better or worse than the CSF biomarkers. Our study is only
a preliminary study, instead multiple studies have examined
CSF to establish sensitivity and specificity of CSF biomarkers.
Moreover, despite thesemany studies, a large variability exists
in the literature as to CSF biomarker diagnostic accuracies
and cut-offs. As biomarker discovery in PBMCs is an ongoing
process and PBMCs biomarkers are still immature, we need
further analysis to enlarge design population.
It will be also of relevance the possibility to utilize
intracellular biomarkers in specific blood cell subpopulations.
In fact the differences in between subjects could also be
due to different composition of their PBMCs pools, even if
separating PBMCs into subpopulations would not permit the
cell-cell interactions required for activation of lymphocytes.
Finally, we assume that the combination of peripheral
and CSF markers may be utilized to categorize patients since
early stages of dementia and to understand mechanisms
underlying dementia.
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